Evidence map›Paper›PMID 40854598›Full record

ArticleImmunoHorizons2025

IL-4 and TGF-β regulate inflammatory cytokines and cellular infiltration in the lung and systemic IL-6 in mouse-adapted SARS-CoV-2 infection.

Solomon Taye Sima, Lucinda Puebla-Clark, Maria Gonzalez-Orozco, Mark Joseph Endrino, Thomas R Shelite, Hsiang-Chi Tseng, Yazmin B Martinez-Martinez, Matthew B Huante, Hannah G Federman, Komi Gbedande and 7 more

Abstract read
In one paragraph

Article in ImmunoHorizons, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Solomon Taye SimaCenter for Immunity and Inflammation, New Jersey Medical School, Rutgers Health, Newark, NJ, United States.
Lucinda Puebla-ClarkDivision of Infectious Diseases, Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX, United States.
Maria Gonzalez-OrozcoDepartment of Pathology, University of Texas Medical Branch, Galveston, TX, United States.
Mark Joseph EndrinoCenter for Immunity and Inflammation, New Jersey Medical School, Rutgers Health, Newark, NJ, United States.
Thomas R SheliteDivision of Infectious Diseases, Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX, United States.
Hsiang-Chi TsengCenter for Virus-Host-Innate Immunity and Department of Medicine, New Jersey Medical School, Rutgers Health, Newark, NJ, United States.
Yazmin B Martinez-MartinezDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, United States.
Matthew B HuanteDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, United States.
Hannah G FedermanCenter for Immunity and Inflammation, New Jersey Medical School, Rutgers Health, Newark, NJ, United States.
Komi GbedandeCenter for Immunity and Inflammation, New Jersey Medical School, Rutgers Health, Newark, NJ, United States.
Vineet D MenacheryDepartment of Pathology, University of Texas Medical Branch, Galveston, TX, United States.
Mark C SiracusaCenter for Immunity and Inflammation, New Jersey Medical School, Rutgers Health, Newark, NJ, United States.
Mark A EndsleyDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, United States.
Sara M DannDivision of Infectious Diseases, Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX, United States.
Janice J EndsleyDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, United States.
Ricardo RajsbaumDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, United States.
Robin StephensCenter for Immunity and Inflammation, New Jersey Medical School, Rutgers Health, Newark, NJ, United States.

Funding

The Role of the Host Ubiquitin System in Promoting SARS-CoV-2 Replication and PathogenesisR01AI166668 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI RAJSBAUM, RICARDO · 2021 to 2025
$2.6M
Identifying host and viral correlates for coronavirus pathogenesisR01AI153602 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI JOHNSON, BRYAN A · 2020 to 2023
$2.0M
The Germinal Center and T cell help in Three Phases of Clearance of PlasmodiumR01AI135061 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI STEPHENS, ROBIN · 2018 to 2022
$2.0M
Mechanisms of Neuroinflammation in Experimental Cerebal MalariaR01NS106597 · NINDS · UNIVERSITY OF TEXAS MED BR GALVESTON · PI STEPHENS, ROBIN, VARGAS, GRACIE · 2018 to 2023
$1.9M
The Host Genetics of Age-Dependent SusceptibilityR21AI145400 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI MENACHERY, VINEET D · 2020 to 2021
$451k
NIAID NIH HHS R01 AI135061NIAID NIH HHS R01 AI153602NIAID NIH HHS R01 AI166668NIAID NIH HHS R21 AI145400NINDS NIH HHS R01 NS106597
6 · The paper itself

Abstract

The pathology of severe COVID-19 is due to a hyperinflammatory immune response persisting after viral clearance. To understand how the immune response to SARS-CoV-2 is regulated to avoid severe COVID-19, we tested relevant immunoregulatory cytokines. Transforming growth factor β (TGF-β), interleukin (IL)-10, and IL-4 were neutralized upon infection with mouse-adapted SARS-CoV-2 (CMA3p20), a model of mild disease; lung inflammation was quantified by histology and flow cytometry at early and late time points. Mild weight loss and lung inflammation including consolidation and alveolar thickening were evident 3 d postinfection (dpi), and inflammation persisted to 7 dpi. Coinciding with early monocytic infiltrates, CCL2 and granulocyte colony-stimulating factor were transiently produced 3 dpi, while IL-12 and CCL5 persisted to 7 dpi, modeling viral and inflammatory phases of disease. Neutralization of TGF-β, but not IL-10 or IL-4, significantly increased lung inflammatory monocytes and elevated serum but not lung IL-6. Neutralization of IL-4 prolonged weight loss and increased early perivascular infiltration without changing viral titer. Anti-IL-4 reduced expression of Arg1, a gene associated with alternative activation of macrophages. Neutralizing TGF-β and IL-4 had differential effects on pathology after virus control. Lung perivascular infiltration was reduced 7 dpi by neutralization of IL-4 or TGF-β, and periairway inflammation was affected by anti-TGF-β, while alveolar infiltrates were not affected by either. Anti-IL-4 prolonged IL-12 to 7 dpi along with reduced IL-10 in lungs. Overall, the immunoregulatory cytokines TGF-β and IL-4 dampen initial inflammation in this mouse-adapted SARS-CoV-2 infection, suggesting that promotion of immunoregulation could help patients in early stages of disease.

Indexed as

COVID-19CytokinesInterleukin-4Interleukin-6LungSARS-CoV-2Transforming Growth Factor betaAnimalsDisease Models, AnimalFemaleInterleukin-10MiceMice, Inbred C57BLCytokinesIl4 protein, mouseInterleukin-10Interleukin-4Interleukin-6Transforming Growth Factor betacytokinesIL-4immunoregulationSARS-CoV-2TGF-β

Identifiers

PMID40854598
PMCPMC12377903

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.